肾癌靶向治疗_省肿瘤大会吴晓安__培训课件.ppt

IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nephrectomy or no nephrectomy followed by interferon?alfa for all patients. The median overall survival in patients who underwent upfront nephrectomy was nearly 6 months longer (P = .001). These data (which are from trials that accrued in the 1990s) resulted in debulking nephrectomy becoming a standard of care for patients who presented with metastatic kidney cancer. * * CI, confidence interval; mRCC, metastatic renal cell carcinoma; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease. ? Other single?arm phase?II trials in the setting of refractory RCC are evaluating these novel agents. This multicenter, single?arm, phase?II trial examined sunitinib in patients who had received previous bevacizumab?based treatment. A partial response rate of 23% was noted, with approximately 75% of patients experiencing some form of tumor burden reduction. Compared with sunitinib in untreated patients, the objective response rate is approximately one half, but the number of patients with reduced tumor burden is similar. IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nephrectomy or no nephrectomy followed by interferon?alfa for all patients. The median overall survival in patients who underwent upfront nephrectomy was nearly 6 months longer (P = .001). These data (which are from trials that accrued in the 1990s) resulted in debulking nephrectomy becoming a standard of care for patients who presented with metastatic kidney cancer. * * CI, confidence interval; mRCC, metastatic renal cell carcinoma; PR, partial response; SD, stable disease. ? Axitinib is a potent small molec